Top Tweets for #NAnt
The SEC's 2026 agenda: 36 proposed rules, two pre-rule items.
Crypto Assets and Crypto Market Structure Amendments carry over from Spring 2025 with a July 2026 target.
Also moving: private market access, lighter disclosure requirements, foreign private issuer reform.
#nant
The SEC and CFTC seek public comment on harmonizing portfolio margining across securities, swaps, and futures.
The stated goal is unlocking liquidity frozen in separate accounts due to jurisdictional overlap. Comments are due 60 days after Federal Register publication.
#nant
The SEC wants to raise the large accelerated filer threshold to $2 billion and simplify filer status into two categories.
This week we break down what that means for issuers and how the proposal reshapes who carries the heaviest reporting burden.
https://t.co/QP2kf5uU2R
#Nant
Les #Pompiers13 présents à #Nant dans l’#Aveyron pour lutter contre un important #FeuDeForêt.
4 sapeurs-#pompiers du @departement13, spécialistes du détachement d’intervention héliporté, #DIH, prêtent main-forte aux collègues en action sur place.
Courage à tous les @PompiersFR
🔥 Des renforts en route pour l’incendie de #Nant dans l’#Aveyron
Près de 40 heures après le début de l’intervention, les sapeurs-pompiers restent pleinement mobilisés sur cet incendie qui a connu une importante réactivation lundi en fin d’après-midi
Alors que le feu avait été fixé dans la nuit de dimanche à lundi, une reprise s’est produite au niveau de la tête de feu, côté flanc gauche. Les flammes progresse dans un secteur particulièrement difficile d’accès et menace plusieurs centaines d’hectares
🚒 Les 80 sapeurs-pompiers déjà engagés vont être renforcés par des détachements spécialisés des SDIS 04, 06, 13 et 30
🚁 Un hélicoptère bombardier d’eau lourd doit également rejoindre le dispositif à partir de 10 h afin d’appuyer les équipes au sol
🤝 Des renforts venus du Gard et de l’Hérault avaient déjà été déployés dès hier pour soutenir les opérations
⚠️ La situation reste évolutive et fait l’objet d’une surveillance étroite
__
📸 Amicale des Sapeurs Pompiers de Pont de Salars
🚫Évitez le secteur
🚒Facilitez l'accès aux secours
#incendie #FeuxDeForêt
🔥 Une reprise est en cours sur l'incendie de #Nant dans l'#Aveyron
🚒✈️ D'importants moyens terrestres et aériens sont à nouveau mobilisés
__
📸 Val Création's
🚫Évitez le secteur
🚒Facilitez l'accès aux secours
#incendie #FeuxDeForêt
🔥 Les #feux de forêt se multiplient en ce lundi 22 juin.
🚨 -> L’un d’eux retient particulièrement l’attention : il s’est déclaré à proximité de #Millau, sur la commune de #Nant. Dans un secteur difficile d’accès, l’#incendie se propage rapidement et a déjà parcouru plus de 30 hectares. D’importants moyens terrestres et aériens sont mobilisés sur place afin de contenir le feu et de limiter sa propagation. 🔥
{📸: @ JEANCLAUDE}
🔥 #Aveyron : l'incendie de #Nant toujours en cours ce lundi matin
Hier soir, le feu avait parcouru 20 hectares dans un secteur difficile d'accès, caractérisé par une pente ascendante favorisant la progression des flammes
🚒 71 sapeurs-pompiers restent mobilisés sur l'intervention. Ils ont été appuyés jusqu'à la tombée de la nuit par d'importants moyens aériens, avec 4 Canadair et 1 Dash-8
__
📸 Faustine Bcqt pour l'association PSFDF (Vidéo prise hier soir)
🚫Évitez le secteur
🚒Facilitez l'accès aux secours
#incendie #FeuxDeForêt
🔥 De nombreux moyens sont actuellement mobilisés à #Nant, dans l'#Aveyron, pour lutter contre un feu de végétation évoluant en pente ascendante, une configuration particulièrement défavorable qui favorise une propagation rapide des flammes
✈️ Dans les airs, 4 Canadair et 1 Dash sont engagés afin de contenir la progression du sinistre et appuyer les équipes au sol
__
📸 Pamela Hawkins
🚫Évitez le secteur
🚒Facilitez l'accès aux secours
#incendie #FeuxDeForêt
🔥 #Feu de végétation en cours commune de #Nant [#Aveyron - 12]
__
📸 TOTEM
🚫Évitez le secteur
🚒Facilitez l'accès aux secours
#incendie #FeuxDeForêt
![asso_psfdf's tweet photo. 🔥 #Feu de végétation en cours commune de #Nant [#Aveyron - 12]
__
📸 TOTEM
🚫Évitez le secteur
🚒Facilitez l'accès aux secours
#incendie #FeuxDeForêt https://t.co/UIoVQp0Qqe](https://pbs.twimg.com/media/HLWhtlqXEAAsuUS.jpg)
$IBRX A blue whale carries about a thousand times more cells than you do. Every one of those cells can, in principle, turn cancerous. By the plain arithmetic of cancer, a creature that large should be riddled with tumors long before it ever reaches the open ocean.
It isn't. Whales live eighty, ninety, past a hundred years, at a size that should be a death sentence, and they do it while barely getting cancer at all.
Biologists have a name for the puzzle: Peto's Paradox. And the answer, as far as we understand it, is that evolution got there first. Whales carry extra copies of the genes that suppress tumors, and DNA repair machinery far more precise than ours. Nature ran the experiment over fifty million years and solved a problem we are still losing to.
On Saturday night, @DrPatrick who built ANKTIVA pointed at that exact fact and posed a riddle. Then he walked away from it.
THE ANTIBODY NATURE ALREADY BUILT
His first message: "Ever wonder why camels, llamas, sharks and whales don't often get cancer?"
The whales are the lesson in resistance. The camels and the sharks are something else: they are the source of a tool.
Camels and llamas make a kind of antibody no human makes. Where ours are large and Y-shaped and built from four pieces, theirs come stripped down to a single small piece, about a tenth the size. Scientists named the working tip of it a nanobody. Sharks evolved their own version of the same trick, separately, in their own branch of the tree of life.
These tiny antibodies are sturdier than ours. They reach into folds and pockets on a target that a full-size antibody is too bulky to touch. They are far easier to engineer. Sharks have been carrying them for something close to four hundred million years, longer than there have been trees on land.
WHAT NATURE ACTUALLY PROVED
Notice how carefully he said it. He wrote that these animals "don't often get cancer," not that they never do. That one word, often, is the honest word, and it is worth pausing on, because the shark has a dark history here. In the 1990s an entire industry sold ground shark cartilage to desperate cancer patients on the false promise that sharks don't get cancer and so their cartilage must cure it. It was a scam, a cruel one, and it was wrong twice over: sharks do get cancer, and the cartilage cured nothing. Soon-Shiong is not repeating that lie. He chose "often" precisely because he knows the difference, and what he is pointing at has nothing to do with cartilage. It is narrower and far more interesting. The shark and the camel did not cure cancer. They invented a better antibody. And the whale is proof that cancer can be held at bay at scale, by a body that evolved the defenses to do it.
Nature, in other words, has already written the proof of principle. Not for a drug. For an idea.
His second message tells you what he wants to build from it: "From Nanobodies to Nantibodies. The goal: ADCC and ADCP. I know that's a foreign language, but I'm sure many will figure that out."
So here is the answer, using only his own words, public biology, and his own company's filings.
THE TWO GUARDS
A week ago, in a post called THE GUARD CANCER CANNOT FOOL, we walked through how the body polices itself. Two cells do the work.
The T cell is an inspector. It can only attack a cell that displays an ID badge, a surface marker called MHC-I, showing what is inside it. Cancer's oldest trick is to take the badge down. No badge, nothing to read, and the inspector lets it pass.
The NK cell runs the opposite rule. It kills any cell that is NOT wearing the badge. So when cancer drops the badge to dodge the inspector, it lights itself up for the NK cell. The move that beats one guard arms the other.
ANKTIVA's job, written into its FDA label, is to wake both of those cells and multiply them. It is an IL-15 receptor agonist. It arms the guards. That was the story, and it was true.
But it was not the whole story, and the riddle is Soon-Shiong telling you where the story breaks.
THE CELL THAT BEATS BOTH
Both guards key off the same badge, in opposite directions. The inspector needs it present. The NK cell needs it absent. So picture the smartest cancer cell of all. It keeps the badge on. And rather than hide from the inspector, it disarms him directly, by waving a chemical flag that orders him to stand down, a flag he is built to obey.
That cell wears the badge, so the NK cell waves it through. It disarms the inspector, so the T cell holds fire. It walks through both checkpoints in the uniform of a healthy cell.
Think of the badge as a fighter jet's transponder, the coded signal that tells your own air defenses "friendly, hold fire," so they don't shoot you out of your own sky. MHC-I is exactly that, for your cells. The clever cancer keeps broadcasting a perfect friendly signal while it jams the one inspector who could see through it. The guns stay silent. It crosses the line untouched.
THE ONE THAT GOT AWAY
Now give that cell a name you know. In a real person, the cell that survives both guards is the one that comes back. It is the recurrence. It is why a patient can finish treatment, ring the bell, scan clean, and then, a year on, hear the word again. The body did not fail to fight. It fought, and it won almost everywhere. But one cell kept its badge, jammed the inspector, and broadcast friendly the whole way through, and one cell is enough.
Arming the guards harder does not reach that cell. A stronger gun still will not fire on something broadcasting friendly. You do not need more firepower. You need a way to mark the enemy that does not depend on the signal it is sending.
THE FORWARD OBSERVER
That is the second half of the riddle, and it rests on a mechanism that is sixty years old.
ADCC, antibody-dependent cellular cytotoxicity, was first described in 1965. It is in every immunology textbook. It is bedrock. Here is how it works, plainly.
- An antibody grabs a specific marker on a target cell with its two tips. Its tail sticks out
- The NK cell carries a receptor, called CD16, that grabs antibody tails
- When CD16 locks onto the tail of an antibody that has tagged a cell, the NK cell kills that cell
In plain language: the antibody is a forward observer who paints the target with a laser. CD16 is the targeting receiver on the NK cell that homes on the paint. And here is the line that closes the gap the recurrence slips through. CD16 does not read the badge. It does not hear the friendly signal. Once a cell is painted, the NK cell fires, no matter what that cell is broadcasting.
ADCP is the same idea with a different soldier. Instead of an NK cell killing the painted target, a macrophage eats it. A second weapon, locked onto the same paint.
The disguise that beat both guards, the badge held high and the inspector jammed, stops working the instant a forward observer paints the cell by a mark it cannot fake.
EVERYTHING IS ALREADY ON THE TABLE
Here is why he could pose the riddle and trust that many would solve it. Every piece is already sitting in plain view.
The antibody format is real, and ancient. The shark has carried it for four hundred million years.
The killing mechanism is real, and old. ADCC has been understood since 1965.
The effector is real, and already built. ImmunityBio engineered a natural killer cell it calls haNK, designed to overexpress "high-affinity CD16" so that it can, in the company's own words, "directly bind to IgG1-type antibodies and enhance cancer killing efficacy" through ADCC. They built the perfect ADCC shooter and have been holding it, waiting for the right antibody to paint the targets.
The synergy is real, and published. ANKTIVA began life under the name ALT-803. Same molecule. In 2014, in the journal Blood, researchers showed that ALT-803 made NK cells markedly better at antibody-directed killing. Paired with rituximab, a real cancer antibody, it boosted NK-cell ADCC against lymphoma in the lab, and in mice the combination sharply reduced the cancer in the bone marrow and beat either drug alone on survival. A later study showed the same effect pairing it with cetuximab against head-and-neck cancer. The exact molecule that is now ANKTIVA was shown, more than a decade ago, to sharpen the very mechanism the antibody depends on.
And the antibody itself is no longer just an idea. Immunotherapy NANTibody LLC is listed as a wholly owned ImmunityBio subsidiary in the company's most recent annual report to the SEC. The entity has been on the books. Saturday night, he switched on the lights.
Read the dots in a row. Nature proved the format. The textbook proved the mechanism. A 2014 paper proved his own molecule supercharges it. The company already built the shooter. The subsidiary already exists. The antibody finds the cell that got away. ANKTIVA wakes the shooter and makes its aim deadlier.
It is, on paper, a complete machine.
THE ONE STEP THAT HASN'T HAPPENED
And here is the truth the science demands we say out loud, because everything above is the blueprint, not the building.
This combination has not been tested in a patient. The Nantibody platform has no published trial, no announced results, no approval. Every piece has been proven on its own. Nature proved the antibody. The textbook proved the mechanism. The lab proved the synergy in a dish and in a mouse. The company proved it could build the cell. But no one has yet put the whole machine together, aimed it at a human cancer, and shown that it works.
That is not a small caveat. It is the entire distance between a beautiful idea and a treatment a person can be given. Biology is littered with machines that were perfect on paper and failed in the body. Until the trial runs, this is a hypothesis with an extraordinary pedigree, and nothing more.
But sit with what that pedigree actually is. The proof of principle is not a model or a slide. It is a shark that has used this antibody for four hundred million years. It is a whale that holds cancer at bay at a scale that should overwhelm it. It is a mechanism science has trusted since 1965, a molecule already published doing the job, an effector cell already engineered to receive it, an entity already incorporated to carry it.
The parts are all on the table. Nature laid most of them there. The only thing that has never been done is to assemble them on purpose and point them at the thing that is killing people. And somewhere right now there is a patient who responded, who rang the bell, who is waiting on exactly that one step that has not yet been taken.
THE GUIDANCE SYSTEM
For two years, the story of this medicine was about waking the immune system up. ANKTIVA armed the guards. The guards caught the cancer that hid by dropping its badge, and the cancer that showed it.
The riddle is about the one that got away. The cell that keeps its badge, jams the inspector, and broadcasts friendly the whole way through. The cell that becomes the recurrence. You do not beat that cell with more firepower. You beat it with a forward observer who paints it by a mark it cannot fake, and a shooter that fires on the paint instead of the signal.
The cancer's entire survival depended on one thing. Broadcasting "I am one of you." The Nantibody does not read the broadcast. It reads the paint.
Nature already proved it can be done. He said many would figure out the rest. Now you have. What is left is not to imagine the machine. It is to build it, and to test it, before the next bell rings.
Tokenization is moving from concept to implementation. Nasdaq, NYSE, and DTCC are all building toward it. Here is what that means for capital markets infrastructure today.
https://t.co/2QbMt3MtJM
#Nant #Tokenization #CapitalMarkets #Blockchain
The SEC’s approval of Nasdaq’s tokenized securities pilot signals continued momentum toward tokenization in regulated markets.
Implementation is now the focus.
#nant #tokenization #capitalmarkets #transferagent #investmentbanking #fintech
https://t.co/jfdEk7YIKd
❄️ #Verglas fréquent ce matin du jeudi 26 mars 2026 en basse montagne avec les #giboulées et en présence de #gel, ici depuis #Nant dans l'#Aveyron. (photo Laurence Pitault)
MiNK Therapeutics Is Presenting at the Inaugural USA-Saudi Biotech Alliance - Jennifer Buell
@jbuell01 @MiNK_iNKT @DrPatrick @ImmunityBio
https://t.co/R4E3W43yMd
#OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #MiNK #Nant #ImmunityBio
A Decade of Work at Nant and ImmunityBio Unveiled - Pat Soon-Shiong
@DrPatrick @ImmunityBio @jbuell01 @MiNK_iNKT
https://t.co/I7jceG5Ciz
#OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #MiNK #Nant #ImmunityBio
ASDIN is proud to partner with the National Association of Nephrology Technicians/Technologists to celebrate National Dialysis Technician Recognition Week 🎉
📅 Happening NEXT WEEK — October 13–18, 2025!
#DialysisTechWeek #HealthcareHeroes #ASDIN #NANT
Last Seen Hashtags on Sotwe
analgesia
Seen from United States
nolimits nolimits
Seen from Pakistan
ipcam
Seen from Belgium
ยโสธรนัดเย็ด
Seen from Thailand
टिटलागढ़
Seen from United States
gayaşk
Seen from Turkey
Memekbasah
Seen from Indonesia
minichat
Seen from Malaysia
ท้องรับงาน
Seen from Thailand
snapchat
Seen from United States
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.5M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.5M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.5M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers